Orthopediatrics CORP 8-K filings

OrthoPediatrics Corp. presented its investor update for August 2026, detailing consistent year-over-year growth, a strong product innovation pipeline, and strategic expansion initiatives in the pediatric orthopedic market.

OrthoPediatrics Corp. stockholders approved the election of directors, executive compensation, and an increase in shares for the 2024 Incentive Award Plan.

OrthoPediatrics reports Q1 2026 revenue of $59.4 million, a 13% increase year-over-year, while reaffirming full-year 2026 guidance.

OrthoPediatrics reported 13% year-over-year revenue growth to $59.4 million and raised its full-year 2026 revenue guidance.

OrthoPediatrics Corp. amended its credit agreement, replacing a $50 million facility with a new $20 million delayed draw term loan, effectively reducing its total committed financing capacity.

OrthoPediatrics Corp. outlines strategic growth initiatives, product pipeline, and financial performance, projecting 2026 revenue of $262M-$266M and breakeven free cash flow.

OrthoPediatrics Corp. announced record full year 2025 revenue of $236.3 million, a 15% increase, alongside significant Q4 free cash flow generation and positive 2026 guidance.

OrthoPediatrics Corp. reports robust preliminary 2025 financial results and outlines strategic initiatives for continued market expansion and innovation in pediatric orthopedics.

OrthoPediatrics Corp. announced record preliminary unaudited full year 2025 revenue of $236.1 million and issued 2026 financial guidance projecting $262-$266 million in revenue and $25 million Adjusted EBITDA.

OrthoPediatrics Corp. presented its investor update, highlighting strong revenue growth, strategic acquisitions, and a positive outlook for 2025.

OrthoPediatrics Corp. reported a 12% year-over-year revenue increase to $61.2 million and a 56% rise in Adjusted EBITDA to $6.2 million for Q3 2025, despite a GAAP diluted loss per share of $(0.50).

OrthoPediatrics Corp. announced preliminary third-quarter 2025 revenue and revised its full-year 2025 financial guidance downwards due to delayed capital and international sales.

OrthoPediatrics Corp. announced the retirement of director Terry Schlotterback and the appointment of Kelly Fischer, CFO of Cook Medical, to its Board of Directors, effective August 8, 2025.

OrthoPediatrics Corp. details its exclusive focus on pediatric orthopedics, strategic growth initiatives, and provides a positive revenue outlook for 2025, despite increased Q2 net losses.

OrthoPediatrics Corp. reported record second-quarter 2025 revenue of $61.1 million, a 16% increase year-over-year, and raised its full-year 2025 revenue guidance.

OrthoPediatrics Corp. announced the expansion of its Specialty Bracing division into new territories, including California, Ohio, Colorado, New York, and its first international market in Ireland.

OrthoPediatrics Corp. announced the successful re-election of its director nominees and the approval of executive compensation and the appointment of Deloitte & Touche LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

OrthoPediatrics Corp. will issue unregistered shares of common stock to settle remaining payments for the acquisition of Medtech Concepts, LLC, replacing previously agreed-upon cash installments.

OrthoPediatrics Corp. outlines its strategy for growth in the pediatric orthopedics market through product innovation, strategic acquisitions, and clinical education.

OrthoPediatrics Corp. announced a 17% increase in first quarter 2025 revenue and raised its full year revenue guidance.

OrthoPediatrics Corp. outlines its growth strategy for 2025, focusing on expanding its product portfolio, increasing market penetration, and continuing its commitment to clinical education in pediatric orthopedics.

OrthoPediatrics Corp. reports a 38% increase in full year 2024 revenue, reaching $204.7 million, and more than doubles fourth quarter 2024 adjusted EBITDA.

OrthoPediatrics Corp. outlines its strategic pillars and growth plans in a new investor presentation, targeting a $235 to $242 million revenue range for 2025.

OrthoPediatrics Corp. reports record preliminary unaudited revenue for full year 2024 and provides financial guidance for 2025, projecting continued growth and profitability.

OrthoPediatrics Corp.'s investor presentation outlines its focus on pediatric orthopedics, highlighting consistent growth, strategic acquisitions, and a commitment to clinical education.

OrthoPediatrics Corp. reported a 37% year-over-year increase in third-quarter revenue and raised its full-year revenue guidance.

OrthoPediatrics Corp. has entered into new employment agreements with its top executives, replacing previous agreements and outlining compensation and severance terms.

OrthoPediatrics presented its growth strategy at an investor day, highlighting its focus on product innovation, market expansion, and achieving profitability.

OrthoPediatrics Corp. finalized a $25 million term loan and issued $50 million in convertible senior notes, both closing on August 12, 2024.

OrthoPediatrics Corp. outlines its strategic focus on pediatric orthopedics, highlighting consistent growth, innovative product development, and strategic acquisitions.